Anti-malarial Drugs Market

Anti-malarial Drugs Market, By Drug Class (Aminoquinolines, Quinoline-methanol (4-quinolinemethanols), Cinchona Alkaloids, Biguanides, Sulfonamides and Sulfones, and Others), By Route of Administration (Oral and Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Plasmodium parasites, a protozoan parasite, are the cause of the widespread infectious disease malaria. A parasite enters the body through the bite of an infected female Anopheles mosquito, which then travels to the liver, where the parasite is produced. Human malaria are generally caused by five types of plasmodium parasites, including P. falciparum, P. malariae, P. ovale, P. vivax, and P.knowlesi. The most dangerous parasite species among these are P. falciparum and P. vivax, which are also the ones responsible for the majority of malaria deaths. Antimalarial drugs are used for the treatment and prevention of malaria infection. Most antimalarial drugs target the erythrocytic stage of malaria infection, which is the phase of infection that causes symptomatic illness. Early diagnosis and efficient treatment are crucial measures to control malaria. Different types of drugs such as quinine, chloroquine, mefloquine, proguanil, primaquine, and others are used in the treatment of malaria. Moreover, some combination drugs such as Pyrimethamine & sulfadoxine, Artemether & lumefantrine, and others are also prescribed for treating the disease.

Market Dynamics

The ongoing research and development for malarial treatment is expected to fuel growth of the market in the forecast period. Various drugs are undergoing the clinical trial for the malarial treatment, which is also expected to drive the market during the forecast period. Moreover, various pharmaceutical companies are actively participating in research and development activities, in order to develop novel drug entity for treatment of malaria. For instance, in November 2022, Novartis AG, a multinational pharmaceutical corporation and Medicines for Malaria Venture (MMV), a product development partnership in the field of antimalarial drug research and development announced decision to move to Phase 3 study for novel non-artemisinin combination to treat uncomplicated malaria. This novel combination also contains an optimized formulation of lumefantrine, which allows it to be given once daily versus the usual twice-daily administration. As the world faces emerging resistance to current malaria treatments, new medicines are needed to continue the fight toward elimination.

Key features of the study:

This report provides in-depth analysis of the global anti-malarial drugs market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global anti-malarial drugs market based on the following parameters–company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study are Ipca Laboratories Ltd., Zydus Group, Merck KGaA, Pfizer Inc., GSK plc., Cipla Inc., Sun Pharmaceutical Industries Ltd., Novartis AG, Alvizia Health Care, Bayer AG, and F. Hoffmann-La Roche Ltd.

Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global anti-malarial drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anti-malarial drugs market

Detailed Segmentation:

Global Anti-malarial Drugs Market, By Drug Class:

Aminoquinolines

Quinoline-methanol (4-quinolinemethanols)

Cinchona Alkaloids

Biguanides

Sulfonamides and sulfones

Others

Global Anti-malarial Drugs Market By Route of Administration:

Oral

Injectable

Global Anti-malarial Drugs Market By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Global Anti-malarial Drugs Market, By Region:

North America

By Country:

U.S.

Canada

Latin America

By Country:

Brazil

Mexico

Argentina

Rest of Latin America

Europe

By Country:

Germany

U.K.

France

Italy

Spain

Russia

Rest of Europe

Asia Pacific

By Country

China

India

Japan

Australia

South Korea

ASEAN

Rest of Asia Pacific

Middle East

By Country:

GCC

Israel

Rest of Middle East

Africa

By Country/Region:

South Africa

Central Africa

North Africa

Company Profiles

Ipca Laboratories Ltd.*

Company Highlights

Products Portfolio

Key Highlights

Financial Performance

Strategies

Zydus Group

Merck KGaA

Pfizer Inc.

GSK plc.

Cipla Inc.

Sun Pharmaceutical Industries Ltd.

Novartis AG

Alvizia Health Care

Bayer AG

F.Hoffmann-La Roche Ltd

“*” marked represents similar segmentation in other categories in the respective section